Published in Cancer Res on December 15, 2006
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem (2008) 4.56
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res (2011) 2.19
Pathways to tamoxifen resistance. Cancer Lett (2007) 2.12
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol (2011) 2.10
Comparative study on ChIP-seq data: normalization and binding pattern characterization. Bioinformatics (2009) 2.02
MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene (2010) 1.97
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics (2009) 1.91
EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol (2010) 1.52
A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology. BMC Genomics (2008) 1.49
GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells. Cancer Res (2009) 1.44
Estrogen induces global reorganization of chromatin structure in human breast cancer cells. PLoS One (2014) 1.43
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat (2008) 1.42
Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol (2009) 1.41
DNA methylation of cancer genome. Birth Defects Res C Embryo Today (2009) 1.39
Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem (2008) 1.37
Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res (2011) 1.37
Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. Cancer Res (2009) 1.37
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res (2008) 1.35
Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res (2012) 1.30
Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics (2008) 1.27
The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia (2012) 1.25
Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem (2011) 1.24
Epigenomics and breast cancer. Pharmacogenomics (2008) 1.23
Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci U S A (2013) 1.16
Genome-wide analysis of alternative promoters of human genes using a custom promoter tiling array. BMC Genomics (2008) 1.15
CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene (2012) 1.12
The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev (2010) 1.09
High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci U S A (2011) 1.07
RNA polymerase II binding patterns reveal genomic regions involved in microRNA gene regulation. PLoS One (2010) 1.07
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biol Ther (2013) 1.05
Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. Epigenetics (2010) 1.05
Inference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data. BMC Syst Biol (2010) 1.03
CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer (2012) 1.03
LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene (2015) 1.03
Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response. J Mammary Gland Biol Neoplasia (2010) 1.02
Epigenetic targeting of ovarian cancer stem cells. Cancer Res (2014) 1.02
Endocrine disruptor regulation of microRNA expression in breast carcinoma cells. PLoS One (2012) 1.00
A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer. BMC Syst Biol (2011) 0.99
Chromatin remodeling in mammary gland differentiation and breast tumorigenesis. Cold Spring Harb Perspect Biol (2010) 0.98
The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance. J Steroid Biochem Mol Biol (2012) 0.98
Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther (2014) 0.95
A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma. Int J Mol Sci (2013) 0.95
Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties. Breast Cancer Res (2013) 0.94
Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet. Cancer Res (2010) 0.94
Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms. Mol Cancer Ther (2008) 0.92
The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res (2014) 0.92
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Mol Pharmacol (2012) 0.90
Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Sci Rep (2012) 0.90
Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Sci Rep (2013) 0.90
Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen. Cancer Biol Ther (2015) 0.90
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PLoS One (2012) 0.89
Multiple roles of COUP-TFII in cancer initiation and progression. J Mol Endocrinol (2012) 0.89
Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models. Endocrinology (2009) 0.89
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines. Curr Med Chem (2007) 0.89
An empirical Bayes model for gene expression and methylation profiles in antiestrogen resistant breast cancer. BMC Med Genomics (2010) 0.88
Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. Breast Cancer Res (2008) 0.85
Interplay between estrogen receptor and AKT in estradiol-induced alternative splicing. BMC Med Genomics (2013) 0.85
High-density array analysis of DNA methylation in Tamoxifen-resistant breast cancer cell lines. Epigenetics (2013) 0.84
MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. PLoS One (2013) 0.84
An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells. BMC Genomics (2012) 0.84
Enriched transcription factor binding sites in hypermethylated gene promoters in drug resistant cancer cells. Bioinformatics (2008) 0.84
Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther (2012) 0.83
Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer (2013) 0.82
Luminal breast cancer metastasis is dependent on estrogen signaling. Clin Exp Metastasis (2012) 0.82
Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. Am J Cancer Res (2012) 0.82
Antiestrogen Resistance and the Application of Systems Biology. Drug Discov Today Dis Mech (2012) 0.82
Synthesis and characterization of fluorescent 4-hydroxytamoxifen conjugates with unique antiestrogenic properties. Bioconjug Chem (2010) 0.81
Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms. Transcription (2012) 0.81
The influence of cis-regulatory elements on DNA methylation fidelity. PLoS One (2012) 0.81
The organochlorine o,p'-DDT plays a role in coactivator-mediated MAPK crosstalk in MCF-7 breast cancer cells. Environ Health Perspect (2012) 0.81
Biologic characteristics of premalignant breast disease. Cancer Biomark (2010) 0.81
Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance. Chin J Cancer (2011) 0.80
Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo. PLoS One (2013) 0.79
Differential regulation of autophagy and cell viability by ceramide species. Cancer Biol Ther (2015) 0.79
A mixture modeling framework for differential analysis of high-throughput data. Comput Math Methods Med (2014) 0.79
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Ann Oncol (2009) 0.79
A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells. Cancer Biol Ther (2012) 0.78
Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review). Oncol Lett (2013) 0.78
Induction of stable drug resistance in human breast cancer cells using a combinatorial zinc finger transcription factor library. PLoS One (2011) 0.77
ELF5 and DOK7 regulation in anti-estrogen treated cells and tumors. Cancer Cell Int (2016) 0.77
Information-dependent enrichment analysis reveals time-dependent transcriptional regulation of the estrogen pathway of toxicity. Arch Toxicol (2016) 0.76
Recent progress and clinical importance on pharmacogenetics in cancer therapy. Clin Chem Lab Med (2011) 0.76
Integrated analysis of DNA methylation profiles and gene expression profiles to identify genes associated with pilocytic astrocytomas. Mol Med Rep (2016) 0.75
A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes. Mol Cancer Res (2016) 0.75
The small heat shock protein B8 (HSPB8) modulates proliferation and migration of breast cancer cells. Oncotarget (2017) 0.75
Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer. Int J Clin Exp Pathol (2015) 0.75
Empirical bayes model comparisons for differential methylation analysis. Comp Funct Genomics (2012) 0.75
5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines. Cancer Lett (2014) 0.75
Mechanisms of Breast Cancer in Shift Workers: DNA Methylation in Five Core Circadian Genes in Nurses Working Night Shifts. J Cancer (2017) 0.75
The complete genome of an individual by massively parallel DNA sequencing. Nature (2008) 52.81
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
A catalog of reference genomes from the human microbiome. Science (2010) 8.10
Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes Dev (2002) 6.74
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell (2012) 5.16
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature (2006) 4.80
A SNP discovery method to assess variant allele probability from next-generation resequencing data. Genome Res (2009) 4.78
How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys (2010) 4.14
Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A (2009) 3.92
Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (2013) 3.90
An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency. Proc Natl Acad Sci U S A (2009) 3.82
MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature (2009) 3.66
FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell (2007) 3.46
Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars. Nat Genet (2013) 3.41
LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One (2007) 2.99
Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol (2012) 2.91
Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res (2002) 2.71
Large scale variation in Enterococcus faecalis illustrated by the genome analysis of strain OG1RF. Genome Biol (2008) 2.71
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70
Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons. Cell (2003) 2.54
Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell (2006) 2.48
Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol (2003) 2.47
The functional consequences of alternative promoter use in mammalian genomes. Trends Genet (2008) 2.47
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med (2011) 2.46
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol (2007) 2.45
Comparison between 1-needle technique versus 2-needle technique for bone marrow aspiration and biopsy procedures. Arch Pathol Lab Med (2013) 2.41
Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes. Nature (2002) 2.41
Universal approximation using incremental constructive feedforward networks with random hidden nodes. IEEE Trans Neural Netw (2006) 2.41
T-bet binding to newly identified target gene promoters is cell type-independent but results in variable context-dependent functional effects. J Biol Chem (2006) 2.24
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase. Oncogene (2003) 2.22
Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer (2004) 2.22
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther (2009) 2.21
Genome sequence of an Australian kangaroo, Macropus eugenii, provides insight into the evolution of mammalian reproduction and development. Genome Biol (2011) 2.18
Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science (2011) 2.17
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology (2011) 2.13
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res (2007) 2.09
Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica (2007) 2.07
MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression. Nucleic Acids Res (2009) 2.03
Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. Cell Biol Int (2006) 2.01
The mechanosensory protein MEC-6 is a subunit of the C. elegans touch-cell degenerin channel. Nature (2002) 2.00
Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol Phys (2011) 1.99
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res (2008) 1.99
Angiosarcoma of the breast. Cancer (2005) 1.98
Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res (2008) 1.98
Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res (2004) 1.97
MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst (2010) 1.94
Type VII collagen is required for Ras-driven human epidermal tumorigenesis. Science (2005) 1.94
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat (2007) 1.92
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol (2012) 1.91
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics (2009) 1.91
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol (2008) 1.91
CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. Nucleic Acids Res (2005) 1.89
Epigenetic resensitization to platinum in ovarian cancer. Cancer Res (2012) 1.88
Alcohol alters DNA methylation patterns and inhibits neural stem cell differentiation. Alcohol Clin Exp Res (2011) 1.88
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics (2007) 1.84
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol (2005) 1.78
Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev (2012) 1.73
Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood (2011) 1.73
CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol Endocrinol (2005) 1.66
FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One (2013) 1.65
MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem (2009) 1.63
Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res (2006) 1.61
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res (2011) 1.58
Evaluation of new reference genes in papaya for accurate transcript normalization under different experimental conditions. PLoS One (2012) 1.56
ChIP-chip comes of age for genome-wide functional analysis. Cancer Res (2006) 1.55
Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Hepatology (2014) 1.55
Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24. Diabetes (2004) 1.54
Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. J Neuroinflammation (2013) 1.53
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry (2009) 1.53
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res (2004) 1.53
Alcohol exposure alters DNA methylation profiles in mouse embryos at early neurulation. Epigenetics (2009) 1.53
DNA methylation of the Trip10 promoter accelerates mesenchymal stem cell lineage determination. Biochem Biophys Res Commun (2010) 1.52